Helius Medical Technologies, Inc. (HSDT)
Market Cap | 2.86M |
Revenue (ttm) | 668,000 |
Net Income (ttm) | -8.87M |
Shares Out | 2.96M |
EPS (ttm) | -12.53 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 41,929 |
Open | 1.010 |
Previous Close | 0.978 |
Day's Range | 0.941 - 1.020 |
52-Week Range | 0.910 - 13.430 |
Beta | 1.59 |
Analysts | Strong Buy |
Price Target | 24.00 (+2,387.05%) |
Earnings Date | Aug 8, 2024 |
About HSDT
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. Heliu... [Read more]
Financial Performance
In 2023, HSDT's revenue was $644,000, a decrease of -18.17% compared to the previous year's $787,000. Losses were -$8.85 million, -37.11% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for HSDT stock is "Strong Buy" and the 12-month stock price forecast is $24.0.
News
![](https://cdn.snapi.dev/images/v1/6/e/press2-2481567.jpg)
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke
-- Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S. registrat...
![](https://cdn.snapi.dev/images/v1/l/v/conf12-2456623.jpg)
Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference
NEWTOWN, PA / ACCESSWIRE / May 31, 2024 / Helius Medical Technologies, Inc., (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation ap...
![](https://cdn.snapi.dev/images/v1/a/4/press7-2445452.jpg)
Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS
Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts
![](https://cdn.snapi.dev/images/v1/8/3/press11-2439620.jpg)
Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
-- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy...
![](https://cdn.snapi.dev/images/v1/f/f/press18-2428070.jpg)
Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results
NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulatio...
![](https://cdn.snapi.dev/images/v1/g/3/conf9-2423987.jpg)
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...
![](https://cdn.snapi.dev/images/v1/x/0/press13-2413715.jpg)
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
NEWTOWN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...
![](https://cdn.snapi.dev/images/v1/w/x/press4-2388095.jpg)
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke -- -- Shepherd Center, a top neurorehabilitation hospital, is the...
![](https://cdn.snapi.dev/images/v1/m/q/214348025-m-normal-none-scaled-2354036.jpg)
Helius Medical stock rallies 40%: explore why
Helius Medical Technologies Inc (NASDAQ: HSDT) is up close to 40% in premarket on Wednesday after teaming up with Lovell Government Services. Why is it good news for Helius Medical stock?
![](https://cdn.snapi.dev/images/v1/d/l/press12-2353828.jpg)
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) -- -- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- ...
![](https://cdn.snapi.dev/images/v1/g/7/press17-2347159.jpg)
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on ...
![](https://cdn.snapi.dev/images/v1/3/x/conf5-2326146.jpg)
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodula...
![](https://cdn.snapi.dev/images/v1/b/f/press10-2319969.jpg)
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month -- -- Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in ...
![](https://cdn.snapi.dev/images/v1/x/g/conf3-2312717.jpg)
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulat...
![](https://cdn.snapi.dev/images/v1/a/8/press14-2305854.jpg)
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) -- -- Proceeds from recent stock issuances thro...
![](https://cdn.snapi.dev/images/v1/c/3/press18-2261550.jpg)
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients -- -- Interaction with FDA on clinical p...
![](https://cdn.snapi.dev/images/v1/t/g/press13-2259474.jpg)
Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists' Ability to Customize PoNS Therapy® to Improve Gait in People with MS
Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States Event Appearance Caps Year of Growth: PoNS®-Trained PTs Now Found Across the United States
![](https://cdn.snapi.dev/images/v1/w/n/press13-2225355.jpg)
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital
-- Brooks Rehabilitation Hospital adds a second site to the registrational program in stroke, and brings the total number of patients to 100 -- -- Study uses Portable Neuromodulation Stimulator (PoNS®...
![](https://cdn.snapi.dev/images/v1/d/v/conf2-2177567.jpg)
Helius Medical Technologies to Present at NobleCon19 Annual Conference
NEWTOWN, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...
![](https://cdn.snapi.dev/images/v1/h/y/press13-2141136.jpg)
Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy™ Helps Patients with Traumatic Brain Injury Return to Work
-- Collaborative project between Pacific Blue Cross and HealthTech Connex designed to reduce long-term disability and improve quality of life for individuals suffering from traumatic brain injury (“TB...
![](https://cdn.snapi.dev/images/v1/t/i/conf15-2137940.jpg)
Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024
-- Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023 -- -...
![](https://cdn.snapi.dev/images/v1/m/w/press12-2100311.jpg)
Helius Medical Technologies, Inc. Receives Letter of Intent from the Québec Ministry of Health and Social Services to Purchase 30 PoNS® Devices
-- PoNS® devices to be provided to a least five sites in five separate administrative regions within Québec ---- Government-funded initiative will evaluate the benefits of PoNS Therapy™ when used by p...
![](https://cdn.snapi.dev/images/v1/g/d/press19-2085436.jpg)
Helius Medical Technologies to Participate at Two Upcoming Healthcare Conferences
NEWTOWN, Pa., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...
![](https://cdn.snapi.dev/images/v1/l/0/press17-2081379.jpg)
Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece
-- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology ---- PoNS system and mouthpiece will be included in pharmacy database utilized by 17 out 20 of the top-grossin...
![](https://cdn.snapi.dev/images/v1/8/s/press5-2072368.jpg)
Helius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference
Company's First-Ever ANPT Booth Sponsorship Enables Specialists to Learn More about this Breakthrough Technology on Eve of National Physical Therapy Month